Compare Fortinet Inc (FTNT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs TransMedics Group Inc — how do they compare? Fortinet Inc trades at $194.57 (market cap $138.75B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Fortinet Inc is far larger — about 50.6× TransMedics Group Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and TransMedics Group Inc for 24 Days on average.
| FTNT | TMDX | |
|---|---|---|
Market Cap | $138.75B | $2.74B |
Volume | 2,956,908 | 949,331 |
Sector | Technology | Health |
52-Week High | $191.27 | $150.42 |
52-Week Low | $75.23 | $61.99 |
Typical Hold Time | 72 Days | 24 Days |
Enterprise Value | $135.17B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $194.75, up 2.89% today and near its 52-week high of $203. The stock shows strong bullish momentum with consistent earnings beats (Q1-Q2 2026) and robust revenue growth from $4.4B in 2022 to $6.8B in 2025. Technical indicators signal bullish moving averages but overbought RSI levels. The company maintains exceptional profitability with 80.2% gross margins and 28.17% net income margins, though valuation multiples remain elevated with P/E at 66.82.
Outlook remains positive driven by cybersecurity demand and AI security tailwinds, with 2026 revenue guidance of $7.5B. Key risks include high valuation sensitivity and competitive pressures. Analyst consensus is mixed (42% Buy, 49% Hold) with $158.64 price target below current levels, suggesting cautious optimism amid strong fundamentals.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
